Across all cancer types, the relative proportion of non-V600 BRAF mutations (Class 2, 3, and Fusions) was higher in older patients (age 60+) compared to younger patients (age < 60) (p < 0.0001) (Figure 4B and Figure S6). Here, BRAF is linked to cancer.